News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA to Meet Sanofi (France) (SAN.PA) Execs Over Violations at Vaccine Plants



7/25/2012 6:49:40 AM

The FDA posted a July 12 warning letter to its website Tuesday involving two Sanofi Pasteur SA vaccine-manufacturing plants. The letter stemmed from plant inspections in Canada and in France that were conducted in March and April of this year. The FDA cited problems with mold at a plant in Toronto, Ontario, and cited a plant in Marcy-l'Etoile, France, because it didn't properly investigate failures of batches or components of certain vaccines. Much of the letter outlined problems involving TheraCys BCG Live, a product used to treat bladder cancer. Sanofi stopped production of that product in order to renovate the Toronto plant, according to the FDA, which has created a shortage of the product.

Read at BioSpace.com
Read at FDA
Read at Bloomberg


comments powered by Disqus
BioSpace.com
FDA
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES